Has John Culleton received payments from drug or device companies?

Yes. Drug and device makers reported $1,454 in general payments to John Culleton across 63 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean John Culleton did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about John Culleton come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

John Culleton

Endocrinology, Diabetes & Metabolism · Florence, SCNPI 1619917309

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $995 of the $1,454 with a category attached, or 68.4%. 20 manufacturers reported payments, led by Abbott at 29.0% of the total. Reporting peaked in 2019 at $660 and has fallen 83.0% since, to $112 in 2022. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in SC, where the typical reported total is $2,665.

$1,454in general payments, 2019–2025

Across 63 payments — averaging $23.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Abbott$421
Insulet Corporation$182
Medtronic$120
Merck$105
Mannkind Corporation$101
Amgen$82
plus $444 from 14 others

What the payments were for

Food & beverage$99568%
Education$40027%
Gifts$594%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Abbott	6	$421
Insulet Corporation	6	$182
Medtronic	2	$120
Merck	8	$105
Mannkind Corporation	4	$101
Amgen(2 entities)	6	$82
Lilly USA, LLC	6	$72
Novo Nordisk	4	$56
Xeris Pharmaceuticals, Inc.	3	$54
Sanofi-aventis U.S. LLC	3	$42
AstraZeneca	3	$37
Corcept Therapeutics	2	$32
Shire North American Group Inc	2	$29
Amarin Pharma, Inc.	2	$26
BD	1	$21
Companion Medical, Inc.	1	$17
Valeritas, Inc.	1	$16
AbbVie	1	$15
IBSA Pharma Inc.	1	$15
Boehringer Ingelheim	1	$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

FreeStyle Lite system$150
Minimed 670G System$104

How this compares

$1,454 in reported general payments places this provider in the 35th percentile of 99 endocrinology, diabetes & metabolism providers in South Carolina.

See all endocrinology, diabetes & metabolism providers in South Carolina →

Other endocrinology, diabetes & metabolism in Florence

Gerald MieleFlorence$35K
Francisco Barrera EchegoyenFlorence$6K
Padigar Shyamanand TantryFlorence$6K
Meenakshi PandeFlorence$5K
Sonika MalikFlorence$4K
Hany ShenoudaFlorence$3K
Melissa Gonzalez LaraFlorence$3K
Gauri DhirMyrtle Beach$417K
Cory WhiteGreenville$413K
Louis HaenelCharleston$377K

See the full list for South Carolina →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →